• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Management of Oligometastatic Prostate Cancer.寡转移前列腺癌的管理
Appl Radiat Oncol. 2020 Sep;9(3):6-10. Epub 2020 Sep 9.
2
Prostate cancer recurrence in patients with negative or equivocal conventional imaging: A role for F-fluciclovine-PET/CT in delineating sites of recurrence and identifying patients with oligometastatic disease.前列腺癌患者常规影像阴性或不确定的复发：F-氟代脱氧葡萄糖-PET/CT 在勾画复发部位和识别寡转移疾病患者中的作用。
Urol Oncol. 2021 Jun;39(6):365.e9-365.e16. doi: 10.1016/j.urolonc.2020.10.017. Epub 2020 Nov 5.
3
Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.寡转移前列腺癌管理的新视角：全面综述。
Eur Urol Oncol. 2019 Mar;2(2):174-188. doi: 10.1016/j.euo.2018.09.005. Epub 2018 Oct 9.
4
A Review of Stereotactic Body Radiation Therapy in the Management of Oligometastatic Prostate Cancer.立体定向体部放射治疗寡转移前列腺癌的研究进展。
Anticancer Res. 2020 May;40(5):2419-2428. doi: 10.21873/anticanres.14211.
5
Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review.正电子发射断层扫描和全身磁共振成像在原发根治性治疗后激素敏感性寡转移前列腺癌转移导向治疗中的应用：一项系统评价。
Eur Urol Oncol. 2021 Oct;4(5):714-730. doi: 10.1016/j.euo.2021.02.003. Epub 2021 Mar 6.
6
A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills?当代寡转移前列腺癌治疗的系统回顾：挑战还是风车？
World J Urol. 2019 Nov;37(11):2343-2353. doi: 10.1007/s00345-019-02652-7. Epub 2019 Jan 31.
7
The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer.寡转移前列腺癌的转移灶定向治疗和原发病灶局部治疗的作用。
Investig Clin Urol. 2017 Sep;58(5):307-316. doi: 10.4111/icu.2017.58.5.307. Epub 2017 Aug 8.
8
Optimal Treatment for Patients with Oligometastatic Prostate Cancer.寡转移前列腺癌患者的最佳治疗方法。
Urol Int. 2022;106(3):217-226. doi: 10.1159/000519386. Epub 2021 Oct 26.
9
[Oligometastatic prostate cancer management].[寡转移前列腺癌的管理]
Prog Urol. 2019 Jun;29 Suppl 1:S20-S34. doi: 10.1016/S1166-7087(19)30167-8.
10
[Treatment of primary oligometastatic prostate cancer].[原发性寡转移前列腺癌的治疗]
Urologe A. 2021 Dec;60(12):1527-1533. doi: 10.1007/s00120-021-01643-0. Epub 2021 Nov 26.

引用本文的文献

1
Emerging Role of Nuclear Medicine in Prostate Cancer: Current State and Future Perspectives.核医学在前列腺癌中的新兴作用：现状与未来展望
Cancers (Basel). 2023 Sep 27;15(19):4746. doi: 10.3390/cancers15194746.
2
Local Therapeutics for the Treatment of Oligo Metastatic Prostate Cancer.局部治疗寡转移性前列腺癌。
Curr Urol Rep. 2023 Oct;24(10):455-461. doi: 10.1007/s11934-023-01173-6. Epub 2023 Jun 28.
3
Is Further Evaluation of Areas with Faint MDP Uptake Needed in Individuals with Oligo-Metastatic Prostatic Adenocarcinoma?寡转移性前列腺腺癌患者中，是否需要对MDP摄取微弱的区域进行进一步评估？
World J Nucl Med. 2022 Oct 28;22(1):40-42. doi: 10.1055/s-0042-1757281. eCollection 2023 Mar.
4
The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors.无细胞游离 DNA 甲基组捕获局部性和转移性前列腺肿瘤之间的差异。
Nat Commun. 2022 Oct 29;13(1):6467. doi: 10.1038/s41467-022-34012-2.
5
Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer.多模态同步寡转移前列腺癌完全消除治疗的疗效和安全性的伴随、前瞻性、二期临床试验的中期分析。
Med Oncol. 2022 Apr 28;39(5):63. doi: 10.1007/s12032-022-01662-7.
6
Imaging of Oligometastatic Disease.寡转移疾病的影像学检查
Cancers (Basel). 2022 Mar 10;14(6):1427. doi: 10.3390/cancers14061427.
7
PSMA Theranostics: Current Landscape and Future Outlook.前列腺特异性膜抗原（PSMA）诊疗一体化：现状与未来展望
Cancers (Basel). 2021 Aug 10;13(16):4023. doi: 10.3390/cancers13164023.

本文引用的文献

1
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial.立体定向消融放疗在寡转移癌综合治疗中的应用：SABR-COMET Ⅱ期随机试验的长期结果。
J Clin Oncol. 2020 Sep 1;38(25):2830-2838. doi: 10.1200/JCO.20.00818. Epub 2020 Jun 2.
2
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.寡转移前列腺癌观察与立体定向消融放疗的结果：ORIOLE 期 2 随机临床试验。
JAMA Oncol. 2020 May 1;6(5):650-659. doi: 10.1001/jamaoncol.2020.0147.
3
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.高风险前列腺癌患者在接受根治性手术或放疗前的前列腺特异性膜抗原 PET-CT（proPSMA）：一项前瞻性、随机、多中心研究。
Lancet. 2020 Apr 11;395(10231):1208-1216. doi: 10.1016/S0140-6736(20)30314-7. Epub 2020 Mar 22.
4
Cancer statistics, 2020.癌症统计数据，2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
5
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation.寡转移疾病的特征描述和分类：欧洲放射肿瘤学会和欧洲癌症研究与治疗组织的共识建议。
Lancet Oncol. 2020 Jan;21(1):e18-e28. doi: 10.1016/S1470-2045(19)30718-1.
6
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.多西他赛联合激素治疗在低负担和高负担转移性激素敏感前列腺癌中的应用：来自 STAMPEDE 试验的长期生存结果。
Ann Oncol. 2019 Dec 1;30(12):1992-2003. doi: 10.1093/annonc/mdz396.
7
F-fluciclovine PET-CT and Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.氟[¹⁸F]氟代脱氧葡萄糖 PET-CT 和镓[⁶⁸Ga]前列腺特异性膜抗原-11 PET-CT 在前列腺癌根治术后早期生化复发患者中的应用：一项前瞻性、单中心、单臂、对比成像试验。
Lancet Oncol. 2019 Sep;20(9):1286-1294. doi: 10.1016/S1470-2045(19)30415-2. Epub 2019 Jul 30.
8
Comparison of 18F-Fluciclovine PET/CT and 99mTc-MDP bone scan in detection of bone metastasis in prostate cancer.18F-氟西克洛维PET/CT与99mTc-MDP骨扫描在前列腺癌骨转移检测中的比较
Nucl Med Commun. 2019 Sep;40(9):940-946. doi: 10.1097/MNM.0000000000001051.
9
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.恩扎卢胺联合标准一线治疗转移性前列腺癌。
N Engl J Med. 2019 Jul 11;381(2):121-131. doi: 10.1056/NEJMoa1903835. Epub 2019 Jun 2.
10
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.阿帕鲁胺治疗转移性去势敏感性前列腺癌。
N Engl J Med. 2019 Jul 4;381(1):13-24. doi: 10.1056/NEJMoa1903307. Epub 2019 May 31.

Management of Oligometastatic Prostate Cancer.

作者信息

Broughman James R, Fleming Christopher W, Mian Omar Y, Stephans Kevin L, Tendulkar Rahul D

机构信息

Dr. Broughman is a PGY4 chief resident, Dr. Fleming is a PGY5 resident, and Dr. Stephans, Dr. Mian, and Dr. Tendulkar are associate staff, all in the Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, OH.

出版信息

Appl Radiat Oncol. 2020 Sep;9(3):6-10. Epub 2020 Sep 9.

PMID:33134438
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7595346/
Abstract
摘要